Robert Bancroft
President, CEO & DirectorMr. Robert Bancroft, also known as Rob, is President, CEO & Director of AEON Biopharma, Inc. from April 29, 2025. Mr. Bancroft brings years of leadership experience in the life sciences industry, spanning biopharmaceuticals, medical devices and healthcare technology. Prior to joining AEON, he served as General Manager of the Therapeutics business at Revance Therapeutics, where he led the launch of Daxxify? in cervical dystonia with a novel strategy that prioritized expert endorsement, payer coverage and reimbursement infrastructure ahead of broader investment - driving strong early adoption and differentiated positioning in the 3B botulinum toxin therapeutics market. Previously, Mr. Bancroft was President of Smith & Nephew's Biotherapeutics division, following the 782M acquisition of Healthpoint Biotherapeutics, where he orchestrated a strategic turnaround that led to four consecutive years of accelerating growth. He also served as Chief Executive Officer of QMENTA, a neuroimaging SaaS startup, where he guided the company through the COVID-19 pandemic and led a successful post-seed funding round. Earlier in his career, Mr. Bancroft held senior leadership roles at Allergan, where he was responsible for global strategy and U.S. commercialization of BOTOX? in multiple therapeutic indications. Mr. Bancroft earned his B.S. in Biology from Indiana University and his M.B.A. from the University of Southern California.
Positions
- Company NameAEON Biopharma, Inc.Stock CodeAEONPositionPresident, CEO & DirectorColleagues
- JFJost FischerIndependent Chairman
- AWAlex WilsonChief Legal & Strategy Officer and Corporate Secretary
- CKChad K. OhChief Medical Officer
- JAJohn A. BencichChief Financial Officer
- JSJennifer SyChief Accounting Officer
- SBShelley B. ThunenIndependent Director
- RJRobert J. PalmisanoIndependent Director
- MFMarc ForthDirector
